Showing 2666 results
- Media Release /CHICAGO, April 25, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening…
- Media Release /Dear SMA community, In January we launched a global Managed Access Program (MAP) for Zolgensma® (onasemnogene abeparvovec). Under this program, we are making up to 100 doses available in 2020 to…
- Media Release /Dear SMA Community, Like many organizations across the United States and around the world, AveXis is closely monitoring the coronavirus disease (COVID-19) and its impact on patients, the SMA…
- Media Release /Dear SMA Community, Since its U.S. approval, AveXis has had increasing demand from families outside of the U.S. for access to AVXS-101. While we are pursuing registration in close to three dozen…
- Media Release /AveXis announces Page Bouchard, DVM has been appointed Senior Vice President of Research and Chief Scientific Officer, effective August 5, 2019. Dr. Bouchard is a 27-year industry veteran with…
Media Library /
Story /Today, many companies are trying to solve global health challenges through philanthropy. However, it has become clear that philanthropy alone is no longer enough to make a lasting impact.
- Media Release /Novartis will present 48 abstracts from its leading MS portfolio, including new data on recently FDA-approved Kesimpta® (ofatumumab)—the first and only self-administered, targeted B-cell therapy for…
- Media Release /New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates and MRI lesion activity and demonstrated…